<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20190801062500Z</creation_date><modification_date>D:20211018072500Z</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-20-1492_h_dec_1.pdf</pdf_file></head><body><section><header>enen</header><p>european commission
 brussels, 18.11.2021c(2021) 8520 (final)</p></section><section><header>commission implementing decisionof 18.11.2021
 on the annual renewal of the conditional marketing authorisation for the orphan 
 medicinal product for human use &quot;tecartus - autologous anti-cd19-transduced cd3+ 
 cells&quot;, granted by decision c(2020) 9284(final)</header><p>(text with eea relevance) (only the dutch text is authentic)</p></section><section><header>en</header><p>1</p></section><section><header>en</header></section><section><header>commission implementing decisionof 18.11.2021
 on the annual renewal of the conditional marketing authorisation for the orphan 
 medicinal product for human use &quot;tecartus - autologous anti-cd19-transduced cd3+ 
 cells&quot;, granted by decision c(2020) 9284(final)</header><p>(text with eea relevance)(only the dutch text is authentic)
 the european commission,
 having regard to the treaty on the functioning of the european union,
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down community procedures for the authorisation and 
 supervision of medicinal products for human and veterinary use and establishing a european 
 medicines agency
 1, and in particular article 10(2) and 14-a thereof,having regard to commission regulation (ec) no 507/2006 on the conditional marketing 
 authorisation for medicinal products for human use falling within the scope of regulation 
 (ec) no 726/2004 of the european parliament and of the council
 2,having regard to the application submitted by kite pharma eu b.v., on 11 june 2021, under 
 article 6(2) of regulation (ec) no 507/2006 with a view to the annual renewal of the 
 conditional marketing authorisation for the medicinal product &quot;tecartus - autologous anti-
 cd19-transduced cd3+ cells&quot;,
 having regard to the opinion of the european medicines agency, formulated on 16 
 september 2021 by the committee for medicinal products for human use,
 whereas:
 (1)
 the medicinal product &quot;tecartus - autologous anti-cd19-transduced cd3+ cells&quot;, 
 entered in the union register of medicinal products under the number eu/1/20/1492 
 and authorised by commission decision c(2020) 9284(final) of 14 december 2020, 
 remains in compliance with the requirements of article 14-a of regulation (ec) no 
 726/2004 of the european parliament and of the council, and regulation (ec) no 
 507/2006,
 (2)
 the conditional marketing authorisation granted by decision c(2020) 9284(final) 
 should therefore be renewed.
 (3)
 the union register of medicinal products should be updated.
 (4)
 the measures provided for in this decision are in accordance with the opinion of the 
 standing committee on medicinal products for human use,
 1oj l 136, 30.4.2004, p. 1.2oj l 92, 30.3.2006, p. 6.</p></section><section><header>en</header><p>2</p></section><section><header>en</header><p>has adopted this decision:article 1the conditional marketing authorisation granted by decision c(2020) 9284(final) of 14 december 2020 is renewed without amendments.
 article 2the period of validity of the renewed authorisation shall be one year from 15 december 2021.
 article 3this decision is addressed to kite pharma eu b.v., tufsteen 1, 2132 nt hoofddorp, nederland.
 done at brussels, 18.11.2021
 for the commissionsandra gallina
 director-general</p></section></body></xml>